No. 1: A strong growth outlook.Keytruda already generates $14 billion in annual revenue. But it is the subject of hundreds of additional studies and is likely to be approved for many more indications.Expect annual sales of the drug to soon top $20 billion.No. 2: Steady cash flow that allows it to pay an attractive dividend.No. 3: A bargain price with PE 11.No. 4: Diversification.No. 5: Finally there will be New Management.Notes from userTrade MRK on T2BF $MRK, Merck & Company, Inc. / H1